MyoKardia, Inc. clinical trials
Acquired by Bristol-Myers Squibb, Nov 17, 2020 · source ↗
The registry lists 7 studies whose lead sponsor is MyoKardia, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 9, 2022.
Before and after it joined Bristol-Myers Squibb
- First submitted before MyoKardia, Inc. became part of Bristol-Myers Squibb
- 7
- First submitted after MyoKardia, Inc. became part of Bristol-Myers Squibb
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 7
Registry sponsor names on this page
- MyoKardia, Inc.7 studies
Something wrong with this grouping? Tell us on the Bristol-Myers Squibb page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Bristol-Myers Squibb studies →
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)CompletedNCT03442764Phase 2
Sponsor listed in the registry: MyoKardia, Inc. · First submitted before MyoKardia, Inc. became part of Bristol-Myers Squibb
- Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyCompletedNCT03470545Phase 3
Sponsor listed in the registry: MyoKardia, Inc. · First submitted before MyoKardia, Inc. became part of Bristol-Myers Squibb
- A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract ObstructionCompletedNCT02842242Phase 2
Sponsor listed in the registry: MyoKardia, Inc. · First submitted before MyoKardia, Inc. became part of Bristol-Myers Squibb
- A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491CompletedNCT03062956Phase 1
Sponsor listed in the registry: MyoKardia, Inc. · First submitted before MyoKardia, Inc. became part of Bristol-Myers Squibb
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy VolunteersCompletedNCT02480296Phase 1
Sponsor listed in the registry: MyoKardia, Inc. · First submitted before MyoKardia, Inc. became part of Bristol-Myers Squibb
- Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461CompletedNCT02329184Phase 1
Sponsor listed in the registry: MyoKardia, Inc. · First submitted before MyoKardia, Inc. became part of Bristol-Myers Squibb
- Single Ascending Dose Study of MYK-461 in Healthy VolunteersCompletedNCT02356289Phase 1
Sponsor listed in the registry: MyoKardia, Inc. · First submitted before MyoKardia, Inc. became part of Bristol-Myers Squibb